Basic Information

Gene symbol LAMP3 Synonyms CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description lysosomal associated membrane protein 3

Gene symbol UL83 Synonyms None Type of gene protein-coding
Description tegument protein pp65

GTO ID GTC0237
Trial ID NCT02366728
Disease Astrocytoma | Glioblastoma
Altered gene UL83|LAMP
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Co-treatment Unpulsed DCs|111In-labeled DCs|Temozolomide
PhasePhase2
Recruitment statusCompleted
TitleEvaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Year2015
CountryUnited States
Company sponsorMustafa Khasraw, MBChB, MD, FRCP, FRACP
Other ID(s)Pro00054740
Vector information
Vectordendritic cell

Clinical Result

Cohort1: Unpulsed DC pre-conditioning
Administration route intradermal injection
Dosage Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 2x10^7, up to a total of 10 DC vaccines
Pts 27
Age Adult, Older_Adult
Outcome Median Overall Survival:16|Percentage of 111In-labeled Dendritic Cells Migrating to the Inguinal Lymph Nodes:6.0|Median Overall Survival in CMV Positive Participants:16.5|Median Overall Survival in CMV Negative Participants:13.4
Adverse reactions 24/27(All-cause mortality); 1/27(Infections and infestations)
References PMID: 32719000
Cohort2: Tetanus pre-conditioning
Administration route intradermal injection
Dosage Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 2x10^7, up to a total of 10 DC vaccines
Pts 28
Age Adult, Older_Adult
Outcome Median Overall Survival:20|Percentage of 111In-labeled Dendritic Cells Migrating to the Inguinal Lymph Nodes:9|Median Overall Survival in CMV Positive Participants:23.8|Median Overall Survival in CMV Negative Participants:16.7
Adverse reactions 22/28(All-cause mortality); 4/28(Infections and infestations; Musculoskeletal and connective tissue disorders; Nervous system disorders; Psychiatric disorders)
References PMID: 32719000
Cohort3: Basiliximab and Tetanus pre-conditioning
Administration route intradermal injection
Dosage Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 2x10^7, up to a total of 10 DC vaccines
Pts 9
Age Adult, Older_Adult
Outcome Median Overall Survival:19|Percentage of 111In-labeled Dendritic Cells Migrating to the Inguinal Lymph Nodes:|Median Overall Survival in CMV Positive Participants:|Median Overall Survival in CMV Negative Participants:
Adverse reactions 6/9(All-cause mortality); 2/9(Gastrointestinal disorders; Musculoskeletal and connective tissue disorders; Nervous system disorders)
References PMID: 32719000

Relationship Graph

Overview of Knowledge Graph